Enliven Therapeutics, Inc.: Vestal Point Capital, LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Vestal Point Capital, LP amended its Schedule 13G filing on Enliven Therapeutics, Inc., updating its beneficial ownership stake with the SEC under accession number 0000902664-26-004579. The filing, submitted via SEC filer CIK 0000902664, reflects a change to the investor's previously reported position in the clinical-stage biopharmaceutical company. Schedule 13G amendments are typically filed by passive investors when their ownership crosses or adjusts relative to the 5% threshold, making the update a signal of shifting institutional interest in the stock. The specific revised share count and percentage were not detailed in the filing summary. Investors will watch for further 13G or 13D filings to gauge whether Vestal Point's position continues to change.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Vestal Point Capital, LP, Enliven Therapeutics, Inc.